Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR : the LEAD study

MLA

Neggers, Sebastian J. C. M. M., et al. Lanreotide Autogel 120 Mg at Extended Dosing Intervals in Patients with Acromegaly Biochemically Controlled with Octreotide LAR : The LEAD Study. 2015. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1233575039&authtype=sso&custid=ns315887.

APA

Neggers, S. J. C. M. M., Pronin, V., Balcere, I., Lee, M.-K., Rozhinskaya, L., Bronstein, M. D., Gadelha, M. R., Maisonobe, P., Sert, C., & van der Lely, A. J. (2015). Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR : the LEAD study.

Chicago

Neggers, Sebastian J C M M, Vyacheslav Pronin, Inga Balcere, Moon-Kyu Lee, Liudmila Rozhinskaya, Marcello D Bronstein, Mônica R Gadelha, Pascal Maisonobe, Caroline Sert, and Aart Jan van der Lely. 2015. “Lanreotide Autogel 120 Mg at Extended Dosing Intervals in Patients with Acromegaly Biochemically Controlled with Octreotide LAR : The LEAD Study.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1233575039&authtype=sso&custid=ns315887.